|Articles|June 20, 2019
IDDI & Roche Identify DFS As Way Forward In Early Breast Cancer
Advertisement
Commissioned by Roche Germany, IDDI has found data that suggests that it is appropriate to use disease-free survival as a surrogate for overall survival in trials in HER-2-positive breast cancer.
To learn more about their findings, click
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck
2
A Shot in the Arm to Traditional Vaccine Trial Strategy
3
SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years
4
Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention
5